stockrow
Friday 6 November 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
31.60
2.02
+6.83%
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) Revenue growth
Cogent Biosciences, Inc.'s revenue growth over the twelve months to 30 September 2020 was 110.2%. Over the past ten years it has ranged from −65.0% (fiscal 2020) to 131.1% (fiscal 2019) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 6.76% and above the Healthcare sector median of 7.98%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2020 | −65.0% | (196.16) |
| FY2019 | 131.1% | 114.70 |
| FY2018 | 16.4% | (15.11) |
| FY2017 | 31.6% | (81.28) |
| FY2016 | 112.8% | 165.84 |
| FY2015 | −53.0% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2020 | −69.4% | 13.76 |
| Jun 2020 | −83.2% | (213.47) |
| Mar 2020 | 130.3% | (171.49) |
| Dec 2019 | 301.8% | 351.86 |
| 11 more quarters | Free account |
Against its own ten years
Low −65.0%
High 131.1%
Ten-year median
24.0%
Current reading's percentile
17
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| SRRK Scholar Rock Holding Corporation compare | 213.7% |
| COGT Cogent Biosciences, Inc. | 110.2% |
| TVTX Travere Therapeutics, Inc. compare | 49.4% |
| DNTH Dianthus Therapeutics, Inc. compare | −11.7% |
| CRSP CRISPR Therapeutics AG compare | −34.3% |
| PTCT PTC Therapeutics, Inc. compare | −35.1% |
| ERAS Erasca, Inc. compare | — |
| MANE Veradermics Incorporated compare | — |
| KOD Kodiak Sciences Inc. compare | — |
| Biotechnology industry median | 6.76% |
| Healthcare sector median | 7.98% |
| Market median | 7.71% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement